
    
      This is a two-arm, randomized, open label, two-center, controlled study to evaluate the
      safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of
      respiratory illness caused by Coronavirus 2019 infection.

      A total of 60 subjects will be randomized 2:1 in this study. 40 patients will be assigned to
      receive daily oral doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours and standard
      care. Other 20 patients will be assigned to receive only standard care.

      Treatment duration: 21 days
    
  